LAUSANNE, SWITZERLAND – Novigenix SA, a leading Swiss biotech that develops and commercializes Immuno-Transcriptomic precision oncology solutions, today announced appointment of Dr. Pedro Romero as Director of Medical & Scientific Affairs. Dr. Romero has previously served on the Medical Advisory Board of Novigenix and brings over three decades of experience in immunology and immune oncology expertise to the team.
Dr. Brian Hashemi, Executive Chairman of Novigenix said:
“We are delighted to welcome Dr. Romero to the team as we expand our biopharma partnerships, and application of ImmunoTranscriptomic precision oncology solutions in drug development and clinical utility programs. Pedro´s tremendous knowledge and expertise in immunology and immunotherapy of cancer patients is particularly relevant as we scale up delivery of unique biopharma solutions to improve patient outcomes”
Dr. Pedro Romero, former Professor of Translational Tumor Immunology and member of the Ludwig Cancer Research Institute said:
“Novigenix has already demonstrated the value of its ImmunoTranscriptomics platform in early detection of cancer and therapy response prediction and monitoring, and the team has tremendous opportunity to deliver previously unknown molecular insights based on its unique data-driven platform. I have very much enjoyed serving on the Medical Advisory Board of the company and am looking forward to joining the team in delivering differentiated solutions that can significantly improve patient outcomes and clinical utility of therapeutic modalities”
About Novigenix
Novigenix is a precision medicine biotech providing a new understanding of the human host immune response to cancer and therapeutic intervention. The Company was founded on the vision that Immuno-Transcriptomics will bring unprecedented advances in diagnosing and treating cancer patients, leading to significant improvement in healthcare. Novigenix’s unique Immuno-Transcriptomic platform enables an accelerated identification of disease specific mRNA signatures of immune cells, which combined with machine learning and predictive algorithms provide precision solutions for detection of disease and response to therapeutic intervention. For more information visit www.novigenix.com
Contacts
Novigenix
Dr. Brian Hashemi, CEO & Chairman
T: +41 788098544
E: brian.hashemi@novigenix.com
